13F Holdings
中文EN

TAK TAKEDA PHARMACEUTICAL CO LTD IFRS Annual reports only

Pharmaceutical Preparations · NYSE · SEC CIK 1395064 · Reporting currency JPY

Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY7.5%
TTM net income YoY-25.1%
TTM EPS YoY-26.3%
Revenue 3-yr CAGR8.7%
Net income 3-yr CAGR-22.3%

Margins

Gross margin65.5%
Operating margin7.5%
Net margin2.4%
FCF margin18.7%
EBITDA margin24.1%

Returns

ROE1.5%
ROA0.7%
ROIC (approx.)1.9%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets51.3%
Debt / equity0.65x
Current ratio1.01x
Interest coverage2.49x

Cash quality & payout

Operating cash flow / net income9.80x
Accruals ratio-6.5%
Payout ratio280.3%
Capex / revenue4.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: JPY FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31FY20212021-03-31
Income statement
Revenue4.58T4.26T4.03T3.57T3.20T
Cost of revenue1.58T1.43T1.24T1.11T994.31B
Gross profit3.00T2.84T2.78T2.46T2.20T
R&D expense730.23B729.92B633.33B526.09B455.83B
Operating income342.59B214.07B490.50B460.84B509.27B
Interest expense137.31B119.53B116.97B122.43B130.81B
Pretax income175.08B52.79B375.09B302.57B366.24B
Income tax66.94B-91.41B58.05B72.41B-9.94B
Net income107.93B144.07B317.02B230.06B376.00B
EBITDA1.10T942.08B1.15T1.04T1.07T
EPS (basic)68.3692.09204.29147.14240.72
EPS (diluted)67.2391.16201.94145.87238.96
Weighted avg. shares (diluted)1.61B1.58B1.57B1.58B1.57B
Balance sheet
Cash & equivalents385.11B457.80B533.53B849.70B966.22B
Receivables709.47B668.40B649.43B696.64B783.09B
Inventory1.22T1.21T986.46B853.17B753.88B
Current assets2.52T2.56T2.40T2.59T2.71T
PP&E, netmay include right-of-use assets (IFRS)1.97T1.99T1.69T1.58T1.45T
Goodwill5.32T5.41T4.79T4.41T4.03T
Intangibles3.63T4.27T4.27T3.82T3.91T
Total assets14.25T15.11T13.96T13.18T12.91T
Current liabilities2.51T2.31T2.48T2.15T1.77T
Short-term debt548.94B367.25B339.60B203.99B22.15B
Long-term debt3.97T4.48T4.04T4.14T4.61T
Total debt4.52T4.84T4.38T4.35T4.64T
Total liabilities7.31T7.83T7.60T7.49T7.74T
Shareholders' equity6.94T7.27T6.35T5.68T5.17T
Net debt4.13T4.39T3.85T3.50T3.67T
Shares outstanding1.59B1.58B1.58B1.58B1.58B
Cash flow statement
Operating cash flow1.06T716.34B977.16B1.12T1.01T
Capital expenditure200.79B175.42B140.66B123.25B111.21B
Free cash flow856.39B540.92B836.50B999.85B899.73B
Investing cash flow-367.06B-463.86B-607.10B-198.12B393.53B
Financing cash flow-751.42B-354.42B-709.15B-1.07T-1.09T
Depreciation & amortization761.40B728.00B664.40B583.15B559.67B
Dividends paid302.50B287.19B279.42B283.67B283.36B
Share buybacks51.86B2.33B26.93B77.53B2.14B

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, JPY, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.